NASDAQ · IMNM
Healthcare · Biotechnology
$24.97
Down-$1.15 (-4.40%)
Updated Sep 11, 2026, 3:05 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
IMNM closed at $24.97 after 20 trading sessions, down 5.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $25.69 | $26.08 | $24.91 | $24.97 | 729.87K |
| Sep 9, 2026 | $26.43 | $26.99 | $26.10 | $26.12 | 784.12K |
| Sep 8, 2026 | $26.15 | $27.245 | $25.91 | $26.81 | 828.62K |
| Sep 4, 2026 | $26.68 | $27.135 | $26.66 | $26.76 | 562.4K |
| Sep 3, 2026 | $27.60 | $28.27 | $26.67 | $27.16 | 796.42K |
| Sep 2, 2026 | $27.56 | $28.485 | $26.81 | $27.33 | 811.1K |
| Sep 1, 2026 | $27.23 | $27.305 | $26.64 | $27.065 | 700.17K |
| Aug 31, 2026 | $27.48 | $27.63 | $27.00 | $27.41 | 1.05M |
| Aug 28, 2026 | $28.45 | $28.77 | $27.40 | $27.57 | 784.51K |
| Aug 27, 2026 | $28.57 | $29.11 | $28.35 | $28.87 | 1.06M |
| Aug 26, 2026 | $29.34 | $29.385 | $28.62 | $28.75 | 559.03K |
| Aug 25, 2026 | $27.88 | $29.72 | $27.88 | $29.385 | 1.93M |
| Aug 24, 2026 | $28.48 | $28.848 | $27.64 | $28.01 | 1.36M |
| Aug 21, 2026 | $28.46 | $29.30 | $28.125 | $28.52 | 848.79K |
| Aug 20, 2026 | $29.13 | $29.15 | $27.89 | $28.08 | 1.03M |
| Aug 19, 2026 | $27.85 | $30.06 | $27.625 | $29.825 | 2.98M |
| Aug 18, 2026 | $27.10 | $27.69 | $26.7598 | $27.56 | 965.34K |
| Aug 17, 2026 | $26.89 | $27.80 | $26.6901 | $27.40 | 1.19M |
| Aug 14, 2026 | $26.38 | $27.30 | $25.59 | $27.20 | 760.76K |
| Aug 13, 2026 | $28.60 | $28.62 | $26.33 | $26.42 | 946.92K |
The latest Smart Investors Daily articles mentioning IMNM.
IMNM research
Company profile and research snapshot.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 12, 2026 | Wedbush | Outperform | — |
| Aug 12, 2026 | Truist Securities | Buy | — |
| Jul 21, 2026 | Wedbush | Outperform | — |
| Jun 12, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Yahoo · Sep 2, 2026
BOTHELL, Wash., September 02, 2026--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET.
SeekingAlpha · Aug 13, 2026
Benzinga · Aug 12, 2026
Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price target from $37 to $38.
Benzinga · Aug 12, 2026
Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $31 to $35.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IMNM.
